Guideline Atlas

Chronic kidney disease

Also known as: chronic renal failure · CKD · ESRD

Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.

United StatesNKF/AUA
CurrentGlobal guideline

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

KDIGO · 2024

This guideline sets out how CKD should be identified, classified by cause, GFR and albuminuria, risk-stratified, and managed to slow progression and limit complications. KDIGO describes it as an update to its 2012 CKD guideline.

  • KDIGO states the 2024 guideline updates the 2012 edition and covers CKD classification, risk assessment, management of complications, medication stewardship and models of care. source
  • KDIGO notes a focused update to the chapter on delaying progression is underway to address newer evidence on SGLT2 inhibitors, GLP-1-based therapies and non-steroidal MRAs. source
EuropeERA/EAU (global: KDIGO)
CurrentGlobal guideline

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

KDIGO · 2024

This guideline sets out how CKD should be identified, classified by cause, GFR and albuminuria, risk-stratified, and managed to slow progression and limit complications. KDIGO describes it as an update to its 2012 CKD guideline.

  • KDIGO states the 2024 guideline updates the 2012 edition and covers CKD classification, risk assessment, management of complications, medication stewardship and models of care. source
  • KDIGO notes a focused update to the chapter on delaying progression is underway to address newer evidence on SGLT2 inhibitors, GLP-1-based therapies and non-steroidal MRAs. source

US vs EU key differences

No curated US/EU comparison yet for this disease.

What changed recently

  1. GLOBAL201220242024-03-01

    The 2024 edition revised almost every statement carried over from the 2012 CKD guideline, keeping only a handful unchanged, and added SGLT2 inhibitors, GLP-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists as proven therapies to slow CKD progression. It also expanded to six chapters with refined GFR assessment and explicit risk-prediction guidance.

    source ↗curation confidence 90%

See the full update feed for changes across every system.